The state of the art in the development of biosimilars

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 3, 2012, Pages 405-417

  McCamish, M ^a   Woollett, G ^b  

^a Sandoz International   (Germany)

^b Avalere Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; ENOXAPARIN; GENERIC DRUG; HUMAN GROWTH HORMONE; HUMAN MENOPAUSAL GONADOTROPIN; HYALURONIDASE; RECOMBINANT GLUCAGON; RECOMBINANT HYALURONIDASE; SALCATONIN;

ARTICLE; FOOD AND DRUG ADMINISTRATION; HUMAN; PRIORITY JOURNAL; PRODUCT DEVELOPMENT;

ANIMALS; BIOSIMILAR PHARMACEUTICALS; BIOTECHNOLOGY; COST-BENEFIT ANALYSIS; DRUG AND NARCOTIC CONTROL; DRUG INDUSTRY; EUROPE; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; PATENTS AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84857233319     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.343     Document Type: Article

References (45)

1. Title VII: Improving Access to Innovative Medical Therapies. Subtitle A: Biologic Price Competition and Innovation (BPCIA) Provisions of the Patient Protection and Affordable Care Act (PPACA ) 〈http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/UCM216146.pdf
2. Public Health Service Act, Title 42 United States Code §262 Regulation of Biological Products 〈http://www.fda.gov/ RegulatoryInformation/Legislation/ucm149278.htm
3. Federal Food, Drug, & Cosmetic Act [21 USC §355] SEC. 505. New Drugs 〈http://www.fda.gov/RegulatoryInformation/Legislation/ FederalFoodDrugandCosmeticActFDCAct/FDCA ctChapterVDrugsandDevices/ucm108125.htm
4. Schiestl, M., Stangler, T., Torella, C., Cepeljnik, T., Toll, H. & Grau, R. Acceptable changes in quality attributes of gylcosylated biopharmaceuticals. Nat. Biotechnol. 29, 310-312 (2011).
5. Casadevall, N. Immune-response and adverse reactions: PRCA case example 〈http://www.ema.europa.eu/docs/en-GB/document-library/Presentation/2009/11/ WC500011064.pdf
6. Sullivan, R., et al. Delivering affordable cancer care in high income countries. The Lancet 12, 933-980 (2011).
7. PhRMA Biotech Medicines in Development, September 2011 〈http://www. phrma.org/sites/default/files/1776/biotech2011.pdf
8. McCamish, M. , MD, PhD presentation. 2011 AAPS Biotechnology Conference, San Francisco, CA , 16 May 2011.
9. PhRMA Biotech Medicines in Development, September 2011 〈http://www. phrma.org/sites/default/files/1776/biotech2011.pdf
10. US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations 〈http://www.accessdata.fda.gov/ scripts/cder/ob/default.cfm〉 (2011).
11. Federal Food, Drug, & Cosmetic Act [21 USC §355] SEC. 505(j). Abbreviated New Drug Applications (ANDA) 〈http://www.fda.gov/ RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCA ct/FDCA ctChapterVDrugsandDevices/ucm108125.htm
12. Federal Food, Drug, & Cosmetic Act [21 USC §355] SEC. 505(b)(2) 〈http://www.fda.gov/RegulatoryInformation/Legislation/ FederalFoodDrugandCosmeticActFDCA ct/FDCA ctChapterVDrugsandDevices/ucm108125. htm
13. FDA Guidance on 505(b)(2) 〈http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm079345.pdf
14. Bioavailability and Bioequivalence Requirements; Abbreviated Applications; Final Rule 〈http://www.fda.gov/OHRMS/DOCKETS/98fr/02-31996. pdf
15. Kozlowski, S., Woodcock, J., Midthun, K. & Sherman, R.B. Developing the nation's biosimilars program. New Engl. J. Med. 365, 385-388 (2011).
16. FDA Response to Sanofi Aventis Citizen Petition on Lovenox, 23 July 2010. Docket Number FDA-2003-P-0273 〈http://www.fda.gov/downloads/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM220083.pdf
17. FDA Response to BIO, GenentecHand Pfizer Citizen Petitions, 30 May 2006. 〈http://www.fda.gov/ohrms/dockets/dockets/04P0231/04P-0231-pdn0001.pdf
18. US Food and Drug Administration. Guidance: Demonstration of Comparability of Human Biological Products, Including Therapeutic Biotechnology-derived Products, Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER) April 1996 〈http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm122879.htm
19. International Conference on Harmonisation. ICH Q5E: Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process. EU: Adopted by CMPM, December 1, 2004, CPMP/ICH/5721/03, date for coming into operation: June 2005; MHLW: Adopted 26 April 2005, PFSB/ELD Notification No. 0426001; FDA: Published in the Federal Register, Vol. 70, No. 125, 30 June 2005 , pp. 37861-37862 〈http://www.ich. org/fileadmin/Public- Web-Site/ICH-Products/Guidelines/Quality/Q5E/Step4/Q5E-Guideline.pdf
20. Usdin, S. Myozyme's zig zags. BioCentury 16, A1-A6 (2008).
21. Follow-on Protein Products. Statement of Janet Woodcock, M.D., Deputy Commissioner, Chief Medical Officer Food and Drug Administration before the House Committee on Oversight and Government Reform, 26 March 2007, and Question and Answer Session 〈http://www.fda.gov/NewsEvents/Testimony/ucm154070.htm
22. A ranesp EPAR 〈http://www.ema.europa.eu/ema/index.jsp?curl=pages/ medicines/human/medicines/000332/human-med-000651. jsp&murl=menus/medicines/ medicines.jsp&mid=WC0b01ac058001d125&js enabled=true
23. A vonex (INTERFERON BETA-1A), BLA 103628 Approval History 〈http://www. accessdata.fda.gov/drugsatfda-docs/label/1996/ifnbbio051796lb. pdf
24. Berlex Laboratories, Inc., Plaintiff, v. Food and Drug Administration, et al., Defendants. James Robertson, United States District Judge 7 October 1996 〈http://www.fda.gov/ohrms/dockets/dockets/04p0171/04p-0171-cp00001-05- exhibit-4.pdf
25. European Public Assessment Report (EPAR) for Aranesp 〈http://www. ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000332/ human-med-000651.jsp&murl=menus/medicines/medicines.jsp&mid= WC0b01ac058001d125&jsenabled=true
26. A ssessing the Impact of a Safe and Equitable Biosimilar Policy in the United States. Statement of Janet Woodcock, M.D., Deputy Commissioner, Chief Medical Officer, Food and Drug Administration before the Subcommittee on Health, House Committee on Energy and Commerce 2 May 2007. 〈http://www.fda.gov/ NewsEvents/Testimony/ucm154017.htm
27. Patient Protection and Affordable Care Act (PPACA ) 〈http://www.gpo. gov/fdsys/pkg/PLAW-111publ148/pdf/PLAW-111publ148.pdf
28. Patient Protection and Affordable Care Act (PPACA ). Title VII: Improving Access to Innovative Medical Therapies. Subtitle A: Biologic Price Competition and Innovation (BPCIA) provisions of the Patient Protection and Affordable Care Act (PPACA )-exclusivity provisions 〈http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/UCM216146.pdf
29. FDA Public Meeting November 2010 Docket Link Federal Register Notice 5 October 10. 〈http://edocket.access.gpo.gov/2010/pdf/2010-24853.pdf〉; Docket number FDA-2010-N-0477; Public submissions: 〈http://www.regulations. gov/#!searchResults;rpp=10;po=0;s=FDA-2010-N-0477
30. FDA Biosimilars User Fee Federal Register Notice 〈http://www.gpo. gov/fdsys/pkg/FR-2011-05-10/pdf/2011-11348.pdf〉. Docket number FDA-2011-N-0326; Public Submissions: 〈http://www.regulations.gov/#!search Results;rpp=10;po=0;s=FDA-2011-N-0326
31. Novartis Submission to docket FDA-2010-N-0477 the November 2010 FDA Public Meeting 〈http://www.regulations.gov/#!documentDetail;D=FDA-2010-N- 0477-0064
32. McCamish, M. & Woolett, G. Worldwide experience with biosimilar development. MAbs 3, 209-217 (2011) 〈http://www.landesbioscience.com/ journals/mabs/article/15005/
33. Follow-on Protein Products. Statement of Janet Woodcock, M.D., Deputy Commissioner, Chief Medical Officer Food and Drug Administration before the House Committee on Oversight and Government Reform, 26 March 2007 〈http://www.fda.gov/NewsEvents/Testimony/ucm154070.htm
34. European Public Assessment Reports (EPARs) for Biosimilar Filgrastims. 〈http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/ epar-search.jsp&mid=WC0b01ac058001d125
35. EMA Guidelines on Comparability/Biosimilarity 〈http://www.ema. europa. eu/ema/index.jsp?curl=pages/regulation/general/general-content-000330. jsp&murl=menus/regulations/regulations.jsp&mid=WC0b01ac058002956b# Comparability Biosimilarity
36. EMA Guidelines for Similar Biological Medicinal Products 〈http://www. ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/ general-content-000408.jsp&murl=menus/regulations/regulations.jsp&mid= WC0b0 1ac058002958c&jsenabled=true
37. EMA Guideline on Similar Biological Medicinal Products containing Monoclonal Antibodies 〈http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2010/11/WC500099361.pdf
38. Kozlowski, S., Woodcock, J., Midthun, K. & Sherman, R.B. Developing the nation's biosimilars program. New Engl. J. Med. 365, 385-388 (2011).
39. CH MP Guideline on Immunogenicity Assessment of Biotechnology-derived Therapeutic Proteins, April 2008 〈http://www.ema.europa.eu/docs/en-GB/ document-library/Scientific-guideline/2009/09/WC500003946.pdf
40. EMA Guideline on Immunogenicity Assessment of Monoclonal Antibodies Intended for In Vivo Clinical Use-Draft 〈http://www.ema.europa.eu/docs/en- GB/document-library/Scientific-guideline/2010/11/WC500099362.pdf
41. EMA Product Specific Approval Documentation 〈http://www.ema. europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar-search. jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124
42. FDA Information on Importation of Drugs Prepared by the Division of Import Operations and Policy 〈http://www.fda.gov/ForIndustry/ImportProgram/ ImportPolicyandInformationbyProduct/default.htm
43. BioCentury Extra for Thursday, 2 June 2011. No FDA Biosimilars Applications Filed 〈http://www.biocentury.com/dailynews/topstory/2011-06- 02/no-fdabiosimilars-applications-filed
44. Kozlowski, S. Presentation at DIA FDLI Biosimilars Meeting, Bethesda, MD, 4-5 May 2011.
45. Patient Protection and Affordable Care Act (PPACA ) 〈http://www.gpo. gov/fdsys/pkg/PLAW-111publ148/pdf/PLAW-111publ148. pdf